Ceritinib in ALK-rearranged non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

http://www.wikidata.org/entity/Q27852989

about

Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach Crizotinib resistance: implications for therapeutic strategies ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology Targeted therapies and immunotherapy in non-small-cell lung cancer Tackling ALK in non-small cell lung cancer: the role of novel inhibitors New targeted treatments for non-small-cell lung cancer - role of nivolumab Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer Immunotherapy for lung cancer Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK inhibitors in non-small cell lung cancer: the latest evidence and developments Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Lung cancer biomarkers, targeted therapies and clinical assays Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib Translating cancer genomes and transcriptomes for precision oncology Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer The distinctive nature of adenocarcinoma of the lung More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Novel targeted agents for the treatment of lung cancer in China The Evolution of Therapies in Non-Small Cell Lung Cancer Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough Predictive biomarkers in precision medicine and drug development against lung cancer Combating acquired resistance to tyrosine kinase inhibitors in lung cancer Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Targeting cancer with kinase inhibitors Ceritinib for ALK-Rearrangement-Positive Non-Small Cell Lung Cancer Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

P2860

000a11e7a8adf088d021ae95ec3075c884c48088 b679f025f562a01da175447506a74605a4d42634 fe9eaad0a58e5bdcdff283a5fd1808db53241e5d

P248

Q24672143-09704BFF-9F4B-4DF8-803C-AB2DBC2A430C Q26738381-29978F85-8C6A-4BD0-A90F-EFE4246B7581 Q26738387-5C451E7D-868E-4919-9468-1C3B7BF5D406 Q26738986-4CCC6D35-A60B-4313-8A05-C2342FE8D1B5 Q26740329-7367EEDA-0E35-4D6A-872B-D8521CC10AE5 Q26740988-A35108ED-776C-4A7C-819D-0D864D7D5804 Q26741009-185A0FD9-5332-4269-BEA5-4ED8EB39F45B Q26741318-F4C10D4A-5144-41FA-8323-64A94F51DF45 Q26741320-93974441-1A0E-45C8-83EB-996F068C1483 Q26741998-1B2BD254-5955-45DF-9635-9ACE75B6B5C8 Q26745427-3148D898-4226-4155-AAAD-4BD195E5E7BD Q26746230-693540A6-2D62-4339-B32D-74793E5CD494 Q26748851-723DD7AD-EFB7-4238-AE25-1A09ECBA7114 Q26751254-FFC04DEC-B460-46E4-8B29-0B206589E272 Q26769659-F1C3A46F-B175-467D-AAD2-CCC3020578EF Q26769879-92AF4951-88B1-4076-AB10-D848310897C6 Q26774625-F806D82C-F51B-4E97-8F02-9891157CC412 Q26775347-956B759A-4984-4A09-9FDF-D87035E0C5AE Q26775394-C7EA9777-A0E7-4D0D-B841-B0C87E2C91B7 Q26775396-D2548455-CA4B-490E-87D0-730CEADA2D89 Q26775817-64A12367-B638-4381-B9AB-F388804A67D9 Q26777081-97074B0D-82A8-4AC1-AB50-53E81B25879F Q26778500-EC2AA43E-8425-42E4-A5C5-7ABCC5011D3A Q26781159-33BA3200-32D6-413E-A7EE-48C5F749FC02 Q26781662-4D6CA6D4-F590-42D9-88B3-031787BFC464 Q26784298-6D9C3223-C28F-478F-ABAB-0A450EB67D8B Q26786580-FDB3B1BE-8689-4569-9A88-68B564CE48C6 Q26786932-31456933-A484-4AA6-824F-CC308A3A73F3 Q26795555-E9171D47-546D-4195-BE78-3AC949D5DF8C Q26795556-2650AB42-000D-42A4-8BB8-DC535B16930F Q26799467-F84C47C4-8894-4B01-9AF7-C9F18A0D239C Q26824536-27777ADF-972A-4F9E-8D53-F5DE644AF687 Q26824877-9A35C2F9-DA33-41C9-A5E4-138D77923FB1 Q26826437-09A9D429-8F5C-448C-91AF-4174242CAC8E Q26851417-F547B7D7-DE97-4358-B6E0-D96E291A55F3 Q26865765-E386EBE0-C79F-4D52-84D9-31088173BD7E Q26996610-1EAFC966-F0F0-43B9-B1D1-DD164821A3A2 Q27004790-FF67C175-AE63-4551-B03D-08B50A94983A Q27010154-AE15CC14-B7D9-4406-8D6B-CA3916308141 Q27023178-4BDCE579-03F6-4139-986F-5A7B32ECF7EF

P2860

Ceritinib in ALK-rearranged non-small-cell lung cancer.

http://www.wikidata.org/entity/Q27852989

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@ast

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@en

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@nl

type

label

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@ast

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@en

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@nl

altLabel

Ceritinib inALK-Rearranged Non–Small-Cell Lung Cancer

@en

prefLabel

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@ast

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@en

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@nl

P1433

Q27852989-60F136C6-EB10-4D8C-8052-F27530BD6271

P1476

Q27852989-37D010E2-1AD5-41FD-8D9B-9140BD72173C

P2093

Q27852989-0318F617-E829-4508-B3AF-3E5EFE04F542

Q27852989-0850DEF5-CAB1-4B0E-A30F-DC063A6B158B

Q27852989-113ABEA8-B809-4A7A-AB01-81E8B05CDC0D

Q27852989-2D1E0D84-BCAF-4BA0-9759-8F2AEADD9DD5

Q27852989-2E54DD88-3DDE-4A48-8548-9ABF5B1694D1

Q27852989-3948A79F-247C-4C13-A08B-2DFA31C00FD9

Q27852989-5A4057A5-6251-4FA8-8E1E-C96D395C97AB

Q27852989-6166A20F-8E45-4671-AABA-D7EE4B5AD427

Q27852989-6BFA71B2-5940-4AD7-AAEE-ADBFB56FA382

Q27852989-780D376E-4E29-4678-868E-4B48D59225BA

P2860

Q27852989-00CCAA0D-EE28-4DD2-BA93-CC1C53F7A2BE

Q27852989-0D812A4A-9834-4FA7-8D38-B6F02C017FED

Q27852989-16BC1FF1-B281-4627-B424-4ECAC559EC01

Q27852989-244954EE-B75F-487E-AC2A-D5FC86F3F163

Q27852989-268B3833-AAEA-47BD-89B6-B38B186732A1

Q27852989-270A99B5-7369-4454-AE36-4099538F6981

Q27852989-36CE81D8-8D37-45B4-A910-FC8E644D2010

Q27852989-41BC1179-86A0-4676-A239-3E449C29927F

Q27852989-440244E8-2F70-41E5-8E10-2E77BBA37CFE

Q27852989-479B3A77-E456-44D5-9FFD-BDCABF8F64B0

P304

Q27852989-7518BA9F-EE6A-49FE-88A0-A5E3952F4851

P31

Q27852989-3919DC45-B841-4BD8-802E-B174D0B4F202

P3181

Q27852989-C540A597-3B7C-4FE5-80AF-3E1EC09885B3

P356

Q27852989-22590802-490B-414D-8FEC-C07816030031

P407

Q27852989-0AD9C49D-4CB7-4EC0-8AC1-3D5A7790676C

P433

Q27852989-6B65A36D-473A-49AA-90C5-52EDA9CEA927

P478

Q27852989-F8F8EA52-C653-4D66-B751-86781B5B9B2C

P50

Q27852989-5087C736-4BDB-442D-B66E-41753D232880

Q27852989-B5625F68-37A2-44FE-A937-40DE42A988A2

Q27852989-E4E94E51-B87D-424E-9047-40827568F724

P577

Q27852989-7D015DD6-D3DF-44A9-8608-323FC9C78DC9

P698

Q27852989-07702A72-43E4-4B09-8A68-73EBECA3E451

P921

Q27852989-F72E8D40-4AD1-473D-B2EE-E8280BB7811C

P932

Q27852989-79669B74-C4C3-46E7-B326-F8F64069C768

P3181

P356

P1433

The New England Journal of Medicine

P1476

Ceritinib in ALK-rearranged non-small-cell lung cancer.

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Anthony L Boral

http://www.w3.org/2001/XMLSchema#string

Benjamin J Solomon

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Daniel S W Tan

http://www.w3.org/2001/XMLSchema#string

Dong-Wan Kim

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Johan Vansteenkiste

http://www.w3.org/2001/XMLSchema#string

Juergen Wolf

http://www.w3.org/2001/XMLSchema#string

P2860

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

P304

1189-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

8421

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1311107

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Armando Santoro

Enriqueta Felip

P577

2014-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24670165

http://www.w3.org/2001/XMLSchema#string

P921

P932

4079055

http://www.w3.org/2001/XMLSchema#string